RecruitingPhase 2Phase 3NCT07229664

Vinpocetine in Patients With Parkinsonian Disease

Clinical Study to Evaluate Safety and Effectiveness of Vinpocetine in Patients With Parkinsonian Disease

Sponsor

Tanta University

Enrollment

60 participants

Start Date

Nov 10, 2025

Study Type

INTERVENTIONAL

Conditions

Parkinson Disease

Summary

The clinical manifestations of Parkinson's disease (PD), a chronic neurodegenerative condition, include resting tremor, hypokinesia, bradykinesia, stiffness and postural instability. These motor symptoms are caused by a selective loss and degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc) region, which leads to a dopamine (DA) insufficiency in the striatum

Eligibility

Min Age: 50 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether vinpocetine, a supplement derived from the periwinkle plant, can benefit people with Parkinson's disease. It may improve blood flow to the brain and protect nerve cells. **You may be eligible if...** - You are 50 years or older - You are male or female - You have been diagnosed with Parkinson's disease and are taking levodopa - Women must have a negative pregnancy test and use effective birth control **You may NOT be eligible if...** - Your Parkinson's is caused by another condition - You have atypical Parkinson's-like syndromes - You are taking anti-inflammatory drugs - You have had brain surgery for Parkinson's - You are pregnant or breastfeeding - You have heart disease, blood clotting disorders, or active cancer - You have a serious alcohol or drug problem Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGLevodopa Carbidopa

Carbidopa/levodopa, also known as levocarb and co-careldopa, is the combination of the two medications carbidopa and levodopa. It is primarily used to manage the symptoms of Parkinson's disease.

DRUGVinpocetine

VIN, a phosphodiesterase-1 (PDE1) inhibitor, reduces oxidative stress and neuroinflammation and is used clinically for cerebrovascular disease and dementia. In PD, VIN increases dopamine levels, protects dopaminergic neurons, reverses motor impairments, and reduces inflammatory mediators